
    
      Patients are randomized to one of three treatment arms: low-dose 3TC plus AZT, high-dose 3TC
      plus AZT, or ddC plus AZT. Treatment continues for 32 weeks, with possible extension to 52
      weeks.

      PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an
      open-label basis. Open-label therapy continues with follow-up every 8 weeks until intolerable
      toxicity occurs or study terminates.
    
  